Member Exclusive News

The week in industry: FDA accepts NDAs for two antibacterial agents from Merck

This week: Kalytera announce positive results in their ongoing CBD study, Recordati gains rights to commercialize JUXTAPID® in Japan and MS patients under Medicare paying more out-of-pocket for treatments.

Feb 07, 2019

Please sign in or register for FREE

No comments yet.